Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Patent & Trademark Office (USPTO) and the European Patent Office (EPO) have issued key patents to Tekmira Pharmaceuticals covering elements of its lipid nanoparticle (LNP) technology, which is used to deliver nucleic acid therapeutics, including small interfering RNA (siRNA).
Subscribe to our email newsletter
Tekmira Pharma said that the EPO has granted claims (European patent no 1 519 714 B1) covering Tekmira’s proprietary manufacturing process and apparatus for the production of lipid nanoparticles.
According to the company, this process has been reviewed by multiple international regulatory agencies for the production of LNPs used in several ongoing human clinical trials.
The USPTO has granted claims (US patent no 7,807,815) covering the identification and modification of siRNA sequence motifs responsible for immune stimulation.
Tekmira Pharma president and CEO Mark Murray said that these patents cover important elements of our LNP technology, which is recognised as the gold standard in the systemic delivery of siRNA.
"The patents cover our proprietary manufacturing process, which supports our ability to advance our own drug development pipeline while also supporting our partners as they advance their programs," Murray said.